Biological Activity of Inorganic Arsenic and Antimony Reflects Oxidation State in Cultured Human Keratinocytes

Chemical Research in Toxicology

Volumn 16, Issue 12, 2003, Pages 1624-1631

  Patterson, Timothy J ^a   Ngo, Mai ^a   Aronov, Pavel A ^a   Reznikova, Tatiana V ^a   Green, Peter G ^b   Rice, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; ARSENIC ACID; ARSENIC TRIOXIDE; INORGANIC COMPOUND; PURINE NUCLEOSIDE PHOSPHORYLASE;

ARTICLE; CELL CULTURE; CELL TYPE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; KERATINOCYTE; METHYLATION; OXIDATION;

ANIMALS; ANTIMONY; ARSENIC; BIOTRANSFORMATION; CATTLE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; ENZYME INHIBITORS; FIBROBLASTS; GUANINE; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; HUMANS; KERATINOCYTES; MEMBRANE PROTEINS; OXIDATION-REDUCTION; PROTEIN PRECURSORS; PURINE-NUCLEOSIDE PHOSPHORYLASE; PYRIMIDINONES; PYRROLES; SPLEEN;

ANIMALIA;

EID: 0347629020     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx034146y     Document Type: Article

References (48)

1. National Research Council (2001) Arsenic in Drinking Water. 2001 Update, pp 1-14, National Academy Press, Washington, DC.
2. Waalkes, M. P., Ward, J. M., Liu, J., and Diwan, B. A. (2003) Transplacental carcinogenicity of inorganic arsenic in the drinking water: Induction of hepatic, ovarian, pulmonary and adrenal tumors in mice. Toxicol. Appl. Pharmacol. 186, 7-17.
3. Bode, A. M., and Dong, Z. (2002) The paradox of arsenic: Molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 42, 5-24.
4. Mann, S., Droz, P.-O., and Vahter, M. (1996) A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application to humans. Toxicol. Appl. Pharmacol. 140, 471-486.
5. Pott, W. A., Benjamin, S. A., and Yang, R. S. H. (2001) Pharmacokinetics, metabolism and carcinogenicity of arsenic. Rev. Environ. Contam. Toxicol. 169, 165-214.
6. Green, H. (1979) The keratinocyte as differentiated cell type. Harvey Lect. 74, 101-138.
7. Jessen, B. A., Qin, Q., Phillips, M. A., Phillips, D. L., and Rice, R. H. (2001) Keratinocyte differentiation marker suppression by arsenic: Mediation by AP1 response elements and antagonism by tetradecanoylphorbol acetate. Toxicol. Appl. Pharmacol. 174, 302-311.
8. Germolec, D. R., Spalding, J., Yu, H. S., Chen, G. S., Simeonova, P. P., Humble, M. C., Bruccoleri, A., Boorman, G. A., Foley, J. F., Yoshida, T., and Luster, M. I. (1998) Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol. 153, 737-745.
9. Hamadeh, H. K., Trouba, K. J., Amin, R. P., Afshari, C. A., and Germolec, D. (2002) Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol. Sci. 69, 306-316.
10. Rea, M. A., Gregg, J. P., Qin, Q., Phillips, M. A., and Rice, R. H. (2003) Global alteration of gene expression in human keratinocytes by inorganic arsenic. Carcinogenesis 24, 747-756.
11. National Research Council (1999) Arsenic in Drinking Water, pp 151-158, National Academy Press, Washington, DC.
12. Thomas, D. J., Styblo, M., and Lin, S. (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol. 176, 127-144.
13. Csanaky, I., and Gregus, Z. (2001) Effect of phosphate transporter and methylation inhibitor drugs on the disposition of arsenate and arsenite in rats. Toxicol. Sci. 63, 29-36.
14. Radabaugh, T. R., Sampayo-Reyes, A., Zakharyan, R. A., and Aposhian, H. V. (2002) Arsenate reductase II. Purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem. Res. Toxicol. 15, 692-698.
15. Huang, R. N., and Lee, T. C. (1996) Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Toxicol. Appl. Pharmacol. 136, 243-249.
16. Vega, L., Styblo, M., Patterson, R., Cullen, W., Wang, C., and Germolec, D. (2001) Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol. Appl. Pharmacol. 172, 225-232.
17. Gebel, T. (1997) Arsenic and antimony: Comparative approach on mechanistic toxicology. Chem.-Biol. Interact. 107, 131-144.
18. Murray, H. W. (2000) Treatment of visceral leishmaniasis (Kala-Azar): A decade of progress and future approaches. Int. J. Infect. Dis. 4, 158-177.
19. Allen-Hoffmann, B. L., and Rheinwald, J. G. (1984) Polycyclic aromatic hydrocarbon mutagenesis of human epidermal keratinocytes in culture. Proc. Natl. Acad. Sci. U.S.A. 81, 7802-7806.
20. Rice, R. H., Steinmann, K. E., deGraffenried, L. A., Qin, Q., Taylor, N., and Schlegel, R. (1993) Elevation of cell cycle control proteins during spontaneous immortalization of human keratinocytes. Mol. Biol. Cell 4, 185-194.
21. Rheinwald, J. G., and Beckett, M. A. (1981) Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous carcinomas. Cancer Res. 41, 1657-1663.
22. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
23. Stoeckler, J. D., Agarwal, R. P., Agarwal, K. C., and Parks, R. J. (1978) Purine nucleoside phosphorylase from human erythrocytes. Methods Enzymol. 51, 530-538.
24. Giulietti, A., Overbergh, L., Valckxx, D., Decalonne, B., Bouillon, R., and Mathieu, C. (2001) An overview of real-time quantitative PCR: Applications to quantify cytokine gene expression. Methods 25, 386-401.
25. Bustin, S. A. (2002) Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J. Mol. Endocrinol. 29, 23-39.
26. Dixon, H. F. (1997) The biochemical action of arsonic acids especially as phosphate analogues. Adv. Inorg. Chem. 44, 191-227.
27. Liu, Z., Shen, J., Carbrey, J. M., Mukhopadhyay, R., Agre, P., and Rosen, B. P. (2002) Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl. Acad. Sci. U.S.A. 99, 6053-6058.
28. Iles, R. A., Stevens, A. N., Griffiths, J. R., and Morris, P. G. (1985) Phosphorylation status of liver by 31P NMR spectroscopy, and its implications for metabolic control. A comparison of 31P NMR spectroscopy (in vivo and in vitro) with chemical and enzymatic determinations of ATP, ADP and Pi. Biochem. J. 229, 141-151.
29. Calderon, R. L., Hudgens, E., Le, X. C., Schreinemachers, D., and Thomas, D. J. (1999) Environ. Health Perspect. 107, 663-667.
30. Radabaugh, T. R., and Aposhian, H. V. (2000) Enzymatic reduction of arsenic compounds in mammalian systems: Reduction of arsenate to arsenite by human liver arsenate reductase. Chem. Res. Toxicol. 13, 26-30.
31. Nemeti, B., and Gregus, Z. (2002) Reduction of arsenate to arsenite in hepatic cytosol. Toxicol. Sci. 70, 4-14.
32. Gregus, Z., and Nemeti, B. (2002) Purine nucleoside phosphorylase as a cytosolic arsenate reductase. Toxicol. Sci. 70, 13-19.
33. Bantia, S., Montgomery, J. A., Johnson, H. G., and Walsh, G. M. (1996) In vitro and in vivo pharmacologica activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Immunopharmacology 35, 53-63.
34. Bantia, S., Miller, P. J., Parker, C. D., Ananth, S. L., Horn, L. L., Kilpatrick, J. M., Morris, P. E., Hutchison, T. L., Montgomery, J. A., and Sandhu, J. S. (2001) Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)- -a novel potent and orally active immunosuppressive agent. Int. Immunopharmacol. 1, 1199-1210.
35. Nemeti, B., and Gregus, Z. (2002) Mitochondria work as reactors in reducing arsenate to arsenite. Toxicol. Appl. Pharmacol. 182, 208-218.
36. Gregus, Z., Gyurasics, A., and Csanaky, I. (2000) Biliary and urinary excretion of in organic arsenic: Monomethylarsonous acid as a major biliary metabolite in rats. Toxicol. Sci. 56, 18-25.
37. Sampayo-Reyes, A., Zakharyan, R. A., Healy, S. M., and Aposhian, H. V. (2000) Monomethylarsonic acid reductase and monomethylarsonous acid in hamster tissue. Chem. Res. Toxicol. 13, 1181-1186.
38. Del Razo, L. M., Styblo, M., Cullen, W. R., and Thomas, D. J. (2001) Determination of trivalent methylated arsenicals in biological matrixes. Toxicol. Appl. Pharmacol. 174, 282-293.
39. Wildfang, E., Radabaugh, T. R., and Aposhian, H. V. (2001) Enzymatic methylation of arsenic compounds. IX. Liver arsenite methyltransferase and arsenate reductase activities in primates. Toxicology 168, 213-221.
40. Zakharyan, R. A., Sampayo-Reyes, A., Healy, S. M., Tsaprailis, G., Board, P. G., Liebler, D. C., and Aposhian, H. V. (2001) Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem. Res. Toxicol. 14, 1051-1057.
41. Buchet, J. P., Lauwerys, R., and Roels, H. (1981) Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int. Arch. Occup. Environ. Health 48, 71-79.
42. Frezard, F., Demicheli, C., Ferreira, C. S., and Costa, M. A. P. (2001) Glutathione-induced conversion of pentavalent antimony to trivalent antimony meglumine antimonate. Antimicrob. Agents Chemother. 45, 913-916.
43. Shaked-Mishan, P., Ulrich, N., Ephros, M., and Zilberstein, D. (2001) Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 276, 3971-3976.
44. Burguera, J. L., Burguera, M., Petit de Pena, Y., Lugo, A., and Anez, N. (1993) Selective determination of antimony (III) and antimony (V) in serum and urine and of total antimony in skin biopsies of patients with cutaneous leishmaniasis treated with meglumine antimonate. Trace Elem. Med. 10, 66-70.
45. Miekeley, N., Mortari, S. R., and Schubach, A. O. (2002) Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis. Anal. Bioanal. Chem. 372, 495-502.
46. Gebel, T. (1998) Suppression of arsenic-induced chromosome mutagenicity by antimony. Mutat. Res. 412, 213-218.
47. Schaumlöffel, N., and Gebel, T. (1998) Heterogeneity of the DNA damage provoked by antimony and arsenic. Carcinogenesis 13, 281-286.
48. Board, P. G., Coggan, M. G. C., Easteal, S. S. J. L., Schulte, G. K., Danley, D. E., Hoth, L. R., Giffor, M. C., Kamath, A. V., Rosner, M. H., Chrunyk, B. A., Perregaux, D. E., Gabel, C. A., Geoghegan, K. F., and Pandit, J. (2000) Identification, characterization, and crystal structure of the omega class glutathione transferases. J. Biol. Chem. 275, 24798-24806.